Rexahn Pharmaceuticals, Inc.’s (RNN) stock price is now at $0.42 Analysts’ mean recommendation stands at 1.70: Stock on the Run

Rexahn Pharmaceuticals, Inc. (RNN)’s Stock Price Trading Update:

Rexahn Pharmaceuticals, Inc. (RNN) ended its day with loss -1.59% and finalized at the price of $0.42. During its last trading session, Stock traded with the total exchanged volume of 4.15 million shares. The average volume stands around 6.74 million shares. The average numbers of shares are traded in a security per day, during the recent 3-month period. The stock has relative volume of 0.62. Relative volume is ratio between current volume and 3-month average value, intraday adjusted. Rexahn Pharmaceuticals, Inc. (RNN) is a part of Healthcare sector and belongs to Biotechnology industry.

Moving Averages:

USA based company, Rexahn Pharmaceuticals, Inc. (RNN)’s latest closing price distance was 63.53% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at -0.30% and -17.47% compared with the 20 Day Moving Average.

Analysts Mean Rating:

Analysts’ mean recommendation for Rexahn Pharmaceuticals, Inc. (RNN) stands at 1.70. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal.

Performance Review:

To review the RNN previous performance, look at its past history, which highlighted below:

During last 5 trades the stock sticks almost -6.04%.

During last one month it showed the change of -17.63%.

During last 3 month it remained at 143.82%.

Along with these its year to date performance is standing at 196.05%.

Important Technical Indicators:

ATR value of company was 0.05. A stock ATR is the difference between the high and low price on any given day. It reveals information about how volatile a stock is. Large ranges indicate high volatility and small ranges indicate low volatility.

Traditional interpretation and usage of the RSI is that RSI values of 70 or above indicate that a security is becoming overbought or overvalued, and therefore may be primed for a trend reversal or corrective pullback in price. On the other side of RSI values, an RSI reading of 30 or below is commonly interpreted as indicating an oversold or undervalued condition that may signal a trend change or corrective price reversal to the upside. Relative Strength Index (RSI) of the company is 45.84. Sudden large price movements can create false buy or sell signals in the RSI. It is, therefore, best used with refinements to its application or in conjunction with other, confirming technical indicators.

The stock volatility for week was 8.55% while for month was 12.14%.The stock, as of last close, traded 230.79% to its 52 week low and was changed -40.83% from its 52 week high. Beta factor, which measures the riskiness of the security, was observed as -0.38. RNN’s value Change from Open was at 1.23% with a Gap of -2.79%.

Earnings per share Details about RNN:

EPS growth in past 5 year was 18.90%.

EPS growth in next year is estimated to reach -12.50% while EPS growth estimate for this year is set at 45.70%.

Three Months Ago Analysts Rating:

Here we discussed Analysts views what they told about Rexahn Pharmaceuticals, Inc. (RNN) stock 3 Months Ago. Analysts recommended an average brokerage rating of Overweight derived from brokerage firms, according to FactSet. 1 said a “Buy Rating” and 1 announced “Overweight Rating”. 0 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”. Analysts play a useful role in our capital markets. For example, by doing in-depth research for their large institutional clients and employers, analysts can help substantial sums of capital be directed to more productive uses in our economy. A “Buy” rating does not mean that every investor should acquire the stock. Nor does a “Sell” rating mean that every investor should immediately sell it. Your own financial situation and investment needs are what matter. If you consider any individual rating, do not views it in absolute or abstract terms, but in the context of your own unique financial situation. In short, whatever a given analyst recommendation may say, always consider whether a particular investment is right for you in light of your own financial circumstances. Remember, you are the boss, it’s your money, and your situation and goals that matter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *